Latest Conference Articles

Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.

Kerstin Junker, MD, associate professor, Department of Urology, Universit

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in prostate cancer during the 2017 EMUC Congress.

Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.

An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.

Alessandro Volpe, MD, University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, discusses the management of locally advanced kidney cancer.

A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.

The addition of incomplete metastasectomy to systemic therapy improved median overall survival by 3 months in patients with metastatic renal cell carcinoma.

Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Christopher Sweeney, MBBS, physician, Dana-Farber Cancer Institute, compares treatment with abiraterone verus docetaxel in patients with prostate cancer.

It has been a “renaissance” in the non–small cell lung cancer landscape with the rapid evolution of targeted treatment for patients with EGFR-mutation–positive disease, says Edward S. Kim, MD.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

The approach to first-line treatment of advanced non-small cell lung cancer (NSCLC) has been evolving rapidly, particularly with respect to patients with lung adenocarcinoma.

Immunotherapy is being positioned as an earlier therapeutic option for patients with high levels of microsatellite instability or mismatch repair deficiency, regardless of their tumor location, expert says.

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

PARP inhibitors offer exciting opportunities to improve outcomes for patients with ovarian cancer and hopefully will be moved to the front-line setting if the evidence warrants it, said Susana M. Campos, MD.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.

The tumor-site agnostic FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) for patients with microsatellite instability-high or mismatch repair deficient solid tumors has helped propel endometrial cancer into the immunotherapy age.

Umesh Mahantshetty, MD, shares his insight on the state of cervical cancer treatment in developing countries.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

As clinicians’ understanding of the disease pathobiology associated with Hodgkin lymphoma (HL) has increased, novel treatments have emerged.

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses updates to the treatment paradigm of high-risk multiple myeloma in an interview during the 2017 Chemotherapy Foundation Symposium.

The next frontier in advancing the field of chronic lymphocytic leukemia (CLL) is identifying patients who will not experience long-term progression-free survival on novel agents.

Because genetic abnormalities play a role in multiple myeloma, it is important to understand these better to improve outcomes, particularly for high-risk patients, said Shaji K. Kumar, MD.

Maintenance therapy with olaparib monotherapy provides clinically significant, long-term treatment benefits and is safe in patients with platinum-sensitive relapsed serous ovarian cancer.